YOLFTbeta
Merck & Company Inc

Merck & Company Inc

MRK · NYSE · Healthcare / Drug Manufacturers - General

147.76USD+0.81 (+0.55%)

Price History

Full chart

Market Stats

Previous Close146.95
Open147.31
Day Range145.24 – 147.99
52-Week Range79.67 – 156.00
Volume6.51M
Market Cap358.41B
P/E (TTM)115.29
Forward P/E9.13
EPS1.26
Dividend Yield2.34%
Beta0.22
50-Day Avg146.64
200-Day Avg125.86

About

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Robert M. Davis J.D.
  • Employees73.00K
  • Headquarters126 East Lincoln Avenue, Rahway, NJ, United States, 07065, USA
  • Websitehttps://www.merck.com

Leadership

  • Mr. Robert M. Davis J.D.Chairman, President & CEO · b. 1967
  • Ms. Caroline A. LitchfieldExecutive VP & CFO · b. 1969
  • Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel · b. 1978
  • Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories · b. 1963
  • Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller · b. 1967
  • Mr. Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
  • Mr. Peter DannenbaumVice President of Investor Relations
  • Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications · b. 1966
  • Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer · b. 1976
  • Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health · b. 1963

Financials

Income Statement

Currency: USD1986-12-311987-12-311988-12-311989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.13B5.06B5.94B6.55B7.67B8.60B9.66B10.50B14.97B16.68B19.83B23.64B26.90B32.71B40.36B21.20B21.45B22.49B22.97B22.01B22.64B24.20B23.85B27.43B45.99B48.05B47.27B44.03B42.24B39.50B39.81B40.12B42.29B39.12B41.52B48.70B59.28B60.12B64.17B64.93B
Growth (%)-+22.58%+17.35%+10.29%+17.11%+12.14%+12.32%+8.65%+42.59%+11.43%+18.87%+19.21%+13.80%+21.62%+23.38%-47.48%+1.16%+4.85%+2.17%-4.18%+2.84%+6.90%-1.44%+15.00%+67.66%+4.48%-1.62%-6.84%-4.08%-6.48%+0.78%+0.79%+5.41%-7.50%+6.13%+17.31%+21.72%+1.40%+6.74%+1.18%
Cost of Revenue1.14B1.23B1.32B1.33B1.52B1.67B1.77B2.11B5.28B6.79B8.59B10.95B13.17B16.39B21.17B3.62B3.91B4.44B4.97B5.15B6.00B6.14B5.58B9.02B18.40B16.87B16.45B16.95B16.77B14.93B14.03B12.91B13.51B12.02B13.62B13.63B17.41B16.13B15.19B18.20B
Gross Profit2.98B3.83B4.62B5.22B6.15B6.93B7.89B8.39B9.69B9.89B11.24B12.68B13.72B16.32B19.20B17.57B17.54B18.05B18.01B16.86B16.63B18.06B18.27B18.41B27.59B31.18B30.82B27.08B25.47B24.56B25.78B27.21B28.79B27.11B27.90B35.08B41.87B43.99B48.98B46.73B
Gross Margin72.29%75.61%77.76%79.72%80.13%80.57%81.63%79.89%64.72%59.30%56.69%53.66%51.02%49.90%47.56%82.90%81.78%80.27%78.38%76.61%73.49%74.62%76.59%67.12%60.00%64.89%65.21%61.50%60.30%62.19%64.75%67.82%68.06%69.29%67.20%72.02%70.63%73.17%76.32%71.98%
Operating Expense1.94B2.46B2.75B2.99B3.50B3.82B4.40B4.50B5.28B5.49B6.26B6.82B7.35B8.73B10.11B8.30B8.45B9.48B11.25B11.00B12.95B12.44B12.18B14.39B24.24B22.20B20.94B19.41B18.79B17.02B20.28B20.41B19.85B19.18B22.35B21.88B23.59B41.03B28.75B23.25B
Operating Income1.04B1.37B1.87B2.24B2.65B3.11B3.49B3.89B4.41B4.40B4.98B5.86B6.38B7.59B9.09B9.28B9.09B8.57B6.76B5.86B3.69B5.62B6.08B4.02B3.35B8.98B9.88B7.67B6.68B7.55B5.50B6.80B8.93B7.93B5.55B13.20B18.28B2.95B20.22B23.49B
Operating Margin25.22%27.05%31.43%34.14%34.56%36.15%36.13%37.01%29.43%26.40%25.14%24.81%23.70%23.21%22.52%43.77%42.38%38.11%29.42%26.62%16.29%23.22%25.51%14.66%7.30%18.68%20.90%17.41%15.82%19.11%13.81%16.94%21.12%20.26%13.36%27.10%30.84%4.91%31.51%36.17%
EBITDA1.24B1.58B2.07B2.46B2.91B3.37B3.81B4.30B5.28B5.26B5.91B6.70B7.39B9.06B10.69B10.41B10.32B9.88B8.21B7.57B5.96B7.61B11.81B18.33B9.75B15.46B16.43B13.33B24.71B12.45B10.82B11.95B13.99B16.01B10.18B17.90B21.32B6.91B25.71B28.26B
EBITDA Margin29.91%31.20%34.88%37.52%37.87%39.21%39.46%40.96%35.28%31.55%29.81%28.35%27.48%27.68%26.47%49.11%48.12%43.95%35.73%34.38%26.31%31.43%49.53%66.81%21.20%32.17%34.76%30.28%58.49%31.52%27.19%29.79%33.08%40.92%24.52%36.75%35.95%11.49%40.06%43.53%
Net Income675.70M906.40M1.21B1.50B1.78B2.12B1.98B2.17B3.00B3.34B3.88B4.61B5.25B5.89B6.82B7.28B7.15B6.83B5.83B4.63B4.43B3.28B7.81B12.90B861.00M6.27B6.17B4.40B11.92B4.44B3.92B2.39B6.22B9.84B7.07B13.05B14.52B365.00M17.12B18.25B
Net Income Margin16.37%17.91%20.32%22.83%23.22%24.66%20.54%20.63%20.02%19.99%19.57%19.52%19.51%18.01%16.90%34.35%33.34%30.38%25.38%21.04%19.59%13.54%32.74%47.03%1.87%13.05%13.05%10.00%28.22%11.25%9.85%5.97%14.71%25.16%17.02%26.79%24.49%0.61%26.68%28.12%
R&D-------1.17B1.23B1.33B1.49B1.68B1.82B2.07B2.34B2.46B2.68B3.28B4.01B3.85B4.78B4.88B4.80B5.84B11.11B8.47B8.17B7.50B7.18B6.70B10.26B10.34B9.75B9.72B13.40B12.24B13.55B30.53B17.94B12.51B
R&D as % of Total Revenue-------11.17%8.22%7.98%7.50%7.12%6.77%6.32%5.81%11.59%12.48%14.59%17.46%17.48%21.13%20.18%20.15%21.31%24.16%17.62%17.28%17.04%17.00%16.97%25.78%25.77%23.06%24.86%32.27%25.14%22.85%50.79%27.95%19.27%
Interest Expense0000000000000000000000251.00M458.00M715.00M749.00M714.00M801.00M732.00M672.00M693.00M754.00M772.00M893.00M831.00M806.00M962.00M1.15B1.27B1.36B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%1.05%1.67%1.55%1.56%1.51%1.82%1.73%1.70%1.74%1.88%1.83%2.28%2.00%1.65%1.62%1.91%1.98%2.09%

Balance Sheet

Currency: USD1986-12-311987-12-311988-12-311989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.11B5.68B6.13B6.76B8.03B9.50B11.09B19.93B21.86B23.83B24.29B25.74B31.85B35.63B39.91B44.02B47.56B40.59B42.57B44.85B44.57B48.35B47.20B112.31B105.78B105.13B106.13B105.64B98.17B101.68B95.38B87.87B82.64B84.40B91.59B105.69B109.16B106.67B117.11B136.87B
Total Liabilities2.54B3.56B3.27B2.73B3.65B3.99B5.46B8.76B9.51B9.81B10.01B11.98B15.35B18.93B20.06B23.13B24.43B21.10B22.88B24.46B24.60B27.76B26.03B50.83B48.98B48.19B50.67B53.32B49.38B56.91B55.07B53.30B55.76B58.40B66.18B67.44B63.10B69.04B70.73B84.20B
Total Equity2.57B2.12B2.86B3.52B3.83B4.92B5.00B10.02B11.14B11.74B11.97B12.59B12.80B13.24B14.83B16.05B18.20B15.58B17.29B17.98B17.56B18.18B18.76B59.06B54.38B54.52B53.02B49.77B48.65B44.68B40.09B34.34B26.70B25.91B25.32B38.18B45.99B37.58B46.31B52.61B
Cash965.80M1.15B1.55B685.10M806.40M797.90M575.10M829.40M1.60B1.85B1.35B1.13B2.61B2.02B2.54B2.14B2.24B1.20B2.88B9.59B5.91B5.34B4.37B9.31B10.90B13.53B13.45B15.62B7.44B8.52B6.51B6.09B7.96B9.68B8.05B8.10B12.69B6.84B13.24B14.56B
Total Debt540.40M1.02B601.60M445.10M917.10M832.10M1.32B2.86B1.29B1.80B1.76B2.25B3.85B6.00B6.92B8.87B8.55B6.80B6.87B8.10B6.84B5.74B6.24B17.47B17.88B17.52B20.57B25.06B21.40B26.41B24.84B24.41B25.11B27.35B33.42B34.63B31.98B36.27B38.27B50.53B
Net Debt-425.40M-130.00M-948.40M-240.00M110.70M34.20M745.80M2.03B-311.40M-51.50M409.60M1.12B1.24B3.98B4.38B6.72B6.31B5.59B3.99B-1.49B921.40M403.30M1.87B8.16B6.98B3.98B7.12B9.44B13.96B17.89B18.33B18.32B17.15B17.68B25.37B26.54B19.29B29.43B25.03B35.97B

Cash Flow

Currency: USD1989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.38B2.06B2.43B2.50B3.05B4.14B2.94B5.43B6.32B5.33B6.13B7.69B9.08B9.53B9.86B8.80B7.61B6.77B7.00B6.57B3.39B10.82B12.38B10.02B11.65B7.86B12.42B10.38B6.45B10.92B13.44B10.25B14.11B19.09B13.01B21.47B16.47B
Investing Cash Flow-558.00M-999.80M-1.30B-1.35B-2.59B-32.40M-1.32B-1.98B-1.60B-11.40M-2.82B-3.64B-4.31B-4.01B-4.23B-1.64B2.27B-4.88B-2.81B-1.83B3.16B-3.50B-2.89B-6.80B-3.15B-374.00M-4.76B-3.21B2.68B4.31B-2.63B-9.44B-16.55B-4.96B-14.08B-7.73B-13.74B
Financing Cash Flow-955.40M-953.70M-1.14B-1.36B-214.20M-3.40B-1.40B-3.84B-4.86B-3.92B-3.87B-3.45B-5.07B-5.53B-6.83B-5.59B-3.04B-5.60B-4.87B-5.52B-1.64B-5.44B-6.90B-3.27B-5.99B-15.11B-5.39B-9.04B-10.01B-13.16B-8.86B-2.83B2.59B-9.12B-4.81B-7.03B-1.92B
Capital Expenditure433.00M670.80M1.04B1.07B1.01B1.01B1.01B1.20B1.45B1.97B2.56B2.73B2.72B2.37B1.92B1.73B1.40B980.20M1.01B1.30B1.46B1.68B1.72B1.95B1.55B2.32B1.28B1.61B1.89B2.62B3.47B4.68B4.45B4.39B3.86B3.37B4.11B
Free Cash Flow947.70M1.38B1.39B1.44B2.04B3.13B1.94B4.23B4.87B3.35B3.57B4.96B6.36B7.16B7.95B7.07B6.21B5.79B5.99B7.17B1.93B9.79B10.66B8.07B10.11B6.54B11.26B8.76B4.56B8.31B9.97B5.57B9.66B14.71B9.14B18.10B12.36B
Dividends Paid650.30M749.40M893.20M1.06B1.17B1.43B1.54B1.73B2.04B2.25B2.59B2.80B3.15B3.19B3.25B3.31B3.35B3.32B3.31B3.28B3.48B4.85B4.81B5.24B5.28B5.25B5.12B5.12B5.17B5.17B5.70B6.21B6.61B7.01B7.45B7.84B8.18B
FCF to OCF68.64%67.37%57.21%57.41%66.78%75.62%65.85%77.95%77.06%62.96%58.23%64.52%69.99%75.13%80.57%80.38%81.56%85.51%85.56%109.15%56.94%90.47%86.09%80.50%86.72%83.24%90.61%84.44%70.78%76.06%74.16%54.32%68.47%77.02%70.30%84.29%75.04%
Dividend Paid to FCF68.62%54.12%64.14%74.02%57.69%45.81%79.42%40.86%41.91%67.16%72.54%56.42%49.49%44.58%40.90%46.81%53.98%57.43%55.23%45.71%180.13%49.57%45.13%64.90%52.22%80.19%45.46%58.48%113.24%62.26%57.14%111.60%68.42%47.68%81.43%43.32%66.15%

Earnings

Report DateJan 23, 1996Apr 17, 1996Jul 18, 1996Oct 16, 1996Jan 28, 1997Apr 16, 1997Jul 17, 1997Oct 16, 1997Jan 27, 1998Apr 16, 1998Jul 21, 1998Oct 16, 1998Jan 26, 1999Apr 23, 1999Jul 23, 1999Oct 21, 1999Jan 26, 2000Apr 24, 2000Jul 24, 2000Oct 20, 2000Jan 23, 2001Apr 20, 2001Jul 20, 2001Oct 18, 2001Jan 22, 2002Apr 18, 2002Jul 19, 2002Oct 18, 2002Jan 28, 2003Apr 21, 2003Jul 21, 2003Oct 22, 2003Jan 27, 2004Apr 22, 2004Jul 21, 2004Oct 21, 2004Jan 25, 2005Apr 21, 2005Jul 21, 2005Oct 24, 2005Jan 31, 2006Apr 20, 2006Jul 24, 2006Oct 20, 2006Jan 30, 2007Apr 19, 2007Jul 23, 2007Oct 22, 2007Jan 30, 2008Apr 21, 2008Jul 21, 2008Oct 22, 2008Feb 3, 2009Apr 21, 2009Jul 21, 2009Oct 22, 2009Feb 16, 2010May 4, 2010Jul 30, 2010Oct 29, 2010Feb 3, 2011Apr 29, 2011Jul 29, 2011Oct 28, 2011Feb 2, 2012Apr 27, 2012Jul 27, 2012Oct 26, 2012Feb 1, 2013May 1, 2013Jul 30, 2013Oct 28, 2013Feb 5, 2014Apr 29, 2014Jul 29, 2014Oct 27, 2014Feb 4, 2015Apr 28, 2015Jul 28, 2015Oct 27, 2015Feb 3, 2016May 5, 2016Jul 29, 2016Oct 25, 2016Feb 2, 2017May 2, 2017Jul 28, 2017Oct 27, 2017Feb 2, 2018May 1, 2018Jul 27, 2018Oct 25, 2018Feb 1, 2019Apr 30, 2019Jul 30, 2019Oct 29, 2019Feb 5, 2020Apr 28, 2020Jul 31, 2020Oct 27, 2020Feb 4, 2021Apr 29, 2021Jul 29, 2021Oct 28, 2021Feb 3, 2022Apr 28, 2022Jul 28, 2022Oct 27, 2022Feb 2, 2023Apr 27, 2023Aug 1, 2023Oct 26, 2023Feb 1, 2024Apr 25, 2024Jul 30, 2024Oct 31, 2024Feb 4, 2025Apr 24, 2025Jul 29, 2025Oct 30, 2025Feb 3, 2026Apr 30, 2026Aug 4, 2026Oct 29, 2026
EPS Estimate0.350.350.400.410.430.420.480.500.510.480.540.560.580.540.610.640.660.620.690.730.750.710.780.840.810.710.770.830.830.760.840.850.620.720.790.730.500.590.620.620.620.730.650.500.510.750.720.690.730.860.830.790.740.780.770.820.780.750.830.830.830.840.940.910.950.981.020.920.810.790.820.880.890.790.810.880.860.750.810.920.910.850.910.990.890.830.871.030.941.001.031.141.031.051.161.241.151.341.091.431.391.611.351.551.521.831.711.711.541.34-2.181.95-0.111.922.141.571.672.142.032.352.01-1.47-0.262.12
EPS Actual0.350.350.400.420.440.420.480.500.520.480.560.560.580.550.610.640.660.630.730.780.750.710.780.840.810.710.770.830.830.760.830.830.620.730.800.600.500.620.620.670.640.780.730.510.500.840.820.750.800.890.860.800.870.740.830.900.790.830.860.850.880.920.950.940.970.991.050.950.830.850.840.920.880.880.850.900.870.850.860.960.930.890.931.070.890.881.011.110.981.051.061.191.041.221.301.511.161.501.371.741.321.401.311.751.802.141.871.851.621.40-2.062.130.032.072.281.571.722.222.132.582.04-1.28-0.13-
Surprise0.00%0.00%0.00%2.44%2.33%0.00%0.00%0.00%1.96%0.00%3.70%0.00%0.00%1.85%0.00%0.00%0.00%1.61%5.80%6.85%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-1.19%-2.35%0.00%1.39%1.27%-17.81%0.00%5.08%0.00%8.06%3.23%6.85%12.31%2.00%-1.96%12.00%13.89%8.70%9.59%3.49%3.61%1.27%17.57%-5.13%7.79%9.76%1.28%10.67%3.61%2.41%6.02%9.52%1.06%3.30%2.11%1.02%2.94%3.26%2.47%7.59%2.44%4.55%-1.12%11.39%4.94%2.27%1.16%13.33%6.17%4.35%2.20%4.71%2.20%8.08%0.00%6.02%16.09%7.77%4.26%5.00%2.91%4.39%0.97%16.19%12.07%21.77%0.87%11.94%25.69%21.68%-5.04%-13.04%-2.96%12.90%18.42%16.94%9.36%8.19%5.19%4.48%5.50%9.23%127.27%7.81%6.54%0.00%2.99%3.74%4.93%9.79%1.49%12.93%50.00%-
Timing-----Pre-marketPre-marketPre-market---------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap358.41B
Enterprise Value405.23B
Trailing P/E115.29
Forward P/E9.13
PEG Ratio0.80
Price / Sales5.38
Price / Book4.56
EPS1.26
Book Value16.99
Revenue (TTM)66.57B
Gross Profit (TTM)50.53B
EBITDA28.87B
Profit Margin4.77%
Operating Margin-0.24%
Return on Equity6.96%
Return on Assets11.87%
Shares Outstanding2.47B
Shares Float2.46B
Beta0.22
Dividend Yield2.34%
Dividend Rate3.40
Payout Ratio105.92%

Analyst Ratings

Buy
Based on 27 analystsTarget 159.76
  • Strong Buy
    14
  • Buy
    5
  • Hold
    8

Ownership Breakdown

Institutions
82.87%
Insiders
0.06%
Retail / Other
17.07%

Top Institutional Holders

  • BlackRock Inc
    227.00M9.20%
  • Vanguard Capital Management, LLC
    161.32M6.54%
  • State Street Corp
    120.41M4.88%
  • Wellington Management Company LLP
    86.25M3.50%
  • Vanguard Portfolio Management, LLC
    67.74M2.75%
  • Geode Capital Management, LLC
    60.74M2.46%
  • Charles Schwab Investment Management Inc
    54.37M2.20%
  • Morgan Stanley - Brokerage Accounts
    48.64M1.97%
  • FMR Inc
    45.44M1.84%
  • JPMorgan Chase & Co
    43.89M1.78%
  • Fisher Asset Management, LLC
    38.52M1.56%
  • NORGES BANK
    36.98M1.50%
  • Bank of America Corp
    30.54M1.24%
  • Northern Trust Corp
    26.28M1.06%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    78.32M3.17%
  • Vanguard 500 Index Investor
    64.79M2.63%
  • iShares Core S&P 500 ETF
    32.87M1.33%
  • Fidelity 500 Index
    32.06M1.30%
  • Schwab US Dividend Equity ETF™
    30.27M1.23%
  • State Street® SPDR® S&P 500® ETF
    30.26M1.23%

Dividends

20263×
0.85Sep 15, 20260.85Jun 15, 20260.85Mar 16, 2026
20254×
0.85Dec 15, 20250.81Sep 15, 20250.81Jun 16, 20250.81Mar 17, 2025
20244×
0.81Dec 16, 20240.77Sep 16, 20240.77Jun 17, 20240.77Mar 14, 2024
20234×
0.77Dec 14, 20230.73Sep 14, 20230.73Jun 14, 20230.73Mar 14, 2023
20224×
0.73Dec 14, 20220.69Sep 14, 20220.69Jun 14, 20220.69Mar 14, 2022
20214×
0.69Dec 14, 20210.65Sep 14, 20210.65Jun 14, 20210.62Mar 12, 2021
20201×
0.62Dec 14, 2020

Stock Splits

  • Jun 3, 20211048:1000
  • Feb 17, 19992:1
  • May 26, 19923:1
  • May 26, 19883:1
  • May 27, 19862:1
  • Jun 1, 19722:1